Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
OncoMed Pharmaceuticals revenue
OncoMed Pharmaceuticals's revenue is $44.4 million.
What is OncoMed Pharmaceuticals's revenue?
- OncoMed Pharmaceuticals's peak quarterly revenue was $20.6M in 2017(q4).
- OncoMed Pharmaceuticals peak revenue was $44.4M in 2018.
- OncoMed Pharmaceuticals annual revenue for 2017 was 38.2M, 51.69% growth from 2016.
- OncoMed Pharmaceuticals annual revenue for 2018 was 44.4M, 16.43% growth from 2017.
- OncoMed Pharmaceuticals's revenue growth from 2012 to 2018 is 79.98%.
- OncoMed Pharmaceuticals has 83 employees, and the revenue per employee ratio is $535,192.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
OncoMed Pharmaceuticals historical revenue
OncoMed Pharmaceuticals's peak revenue was $44.4M in 2018. The peak quarterly revenue was $20.6M in 2017(q4).
OncoMed Pharmaceuticals's revenue increased from $24.7m in 2012 to $44.4M currently. That's a 79.98% change in annual revenue.
OncoMed Pharmaceuticals annual revenue
OncoMed Pharmaceuticals annual revenue over time
| Fiscal year / year | OncoMed Pharmaceuticals revenue |
|---|---|
| 2012 | $24.7M |
| 2013 | $37.8M |
| 2014 | $39.6M |
| 2015 | $25.9M |
| 2016 | $25.2M |
| 2017 | $38.2M |
| 2018 | $44.4M |
How accurately did OncoMed Pharmaceuticals' revenue projections match actual performance?
OncoMed Pharmaceuticals annual growth
OncoMed Pharmaceuticals saw the greatest revenue growth in 2013, when revenue increased by 53.07%.
OncoMed Pharmaceuticals had the lowest revenue growth in 2015, when revenue changed by -34.53%.
OncoMed Pharmaceuticals annual growth rate over time
| Year | OncoMed Pharmaceuticals growth |
|---|---|
| 2013 | 53%↑ |
| 2014 | 5%↑ |
| 2015 | -35%↓ |
| 2016 | -3%↓ |
| 2017 | 52%↑ |
| 2018 | 16%↑ |
OncoMed Pharmaceuticals quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
OncoMed Pharmaceuticals quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2013 | - | $2.9M | $12.9M | $19.0M |
| 2014 | $6.0M | $6.0M | $19.0M | $8.5M |
| 2015 | $9.7M | $4.7M | $4.7M | $6.8M |
| 2016 | $6.4M | $6.7M | $5.9M | $6.2M |
| 2017 | $6.2M | $6.2M | $5.1M | $20.6M |
| 2018 | $7.8M | $6.9M | $19.5M | $10.2M |
OncoMed Pharmaceuticals jobs nearby
Do you work at OncoMed Pharmaceuticals?
Is OncoMed Pharmaceuticals transparent about its revenue structure?
OncoMed Pharmaceuticals financial information
| CEO | Paul J Hastings |
| Company Type | Public |
| Employees Number | 83 |
| Date Founded | 2004 |
| Headquarters | Redwood City, California |
| Number of Locations | 1 |
| Revenue | $44.4M |
| Net Income | -$8,101,000 |
| PE Ratio | -3.63 |
| Tax Rate | 0.0% |
| Market Capitalization | $29.4M |
| Total Assets | $65,078,000 |
| Ticker | OMED |
OncoMed Pharmaceuticals jobs you might like
OncoMed Pharmaceuticals financing
OncoMed Pharmaceuticals received early financing of $13.9M on 2005-09-07.
| Series | Round size | Date |
|---|---|---|
| Series A | $13.9M | 09/2005 |
| Series B | $154M | 11/2008 |
| Series Unknown | $20M | 04/2011 |
| Post Ipo Equity | $22.2M | 12/2013 |
OncoMed Pharmaceuticals investors
| Investors | Security type |
|---|---|
| Latterell Venture Partners | Series A |
| The Vertical Group | Series A |
| U.S. Venture Partners (USVP) | Series A |
| Morgenthaler Ventures | Series A |
| Delphi Ventures | Series B |
| Latterell Venture Partners | Series B |
| Bay Partners | Series B |
| The Vertical Group | Series B |
| Adams Street Partners | Series B |
| DE NOVO VENTURES | Series B |
| U.S. Venture Partners (USVP) | Series B |
| Morgenthaler Ventures | Series B |
| Phase4 Ventures | Series B |
OncoMed Pharmaceuticals competitors
OncoMed Pharmaceuticals's top competitor, Merck, earned an annual revenue of $64.2B.
OncoMed Pharmaceuticals's smallest competitor is Human Genome Sciences with revenue of $131.0M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Amneal Pharmaceuticals | $76,227 | $2.8B | 6,500 | 104 |
| Merck | $90,328 | $64.2B | 74,000 | 2,442 |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 227 |
| Amgen | $93,349 | $33.4B | 22,000 | 641 |
| Zoetis | $87,092 | $9.3B | 11,300 | 183 |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 445 |
| Sanofi Genzyme | $84,495 | $4.6B | 12,000 | - |
| Upsher-Smith Laboratories | $63,937 | $420.0M | 550 | 30 |
| Seagen | $85,008 | $2.0B | 900 | - |
| Human Genome Sciences | $70,157 | $131.0M | 1,000 | - |
OncoMed Pharmaceuticals revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
OncoMed Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of OncoMed Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about OncoMed Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at OncoMed Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by OncoMed Pharmaceuticals. The data presented on this page does not represent the view of OncoMed Pharmaceuticals and its employees or that of Zippia.
OncoMed Pharmaceuticals may also be known as or be related to ONCOMED PHARMACEUTICALS INC, OncoMed Pharmaceuticals, OncoMed Pharmaceuticals Inc, OncoMed Pharmaceuticals, Inc. and Oncomed Pharmaceuticals, Inc.